Sales of Eli Lilly’s (LLY) blockbuster weight-loss ... Zepbound sales reached $1.9 billion in the fourth quarter of 2024, compared with $176 million during the same period in 2023 — when it ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link between vision loss and taking the weight loss and diabetes drugs such as ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug Zepbound and diabetes ... with its forecast from last month that fell below analysts ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments ... sales for its Zepbound and Mounjaro of $1.91 billion and $3.53 billion respectively, in ...

The company said last month that it expected to report sales of diabetes drug Mounjaro and weight-loss treatment Zepbound below analysts' expectations for a second quarter in a row. The US ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ... including Mounjaro and Zepbound, are administered weekly via injection ...

The pharma giant has had a few hits and misses in the past few months: The FDA removed ... for diabetes, and Zepbound, for weight loss. Mounjaro brought in $11.5 billion alone, a 124% increase ...